The global sales of extracorporeal membrane oxygenation machines are estimated to be worth USD 582.2 million in 2024 and are anticipated to reach a value of USD 904.1 million by 2034. Sales are projected to rise at a CAGR of 4.5% over the forecast period between 2024 and 2034. The revenue generated by extracorporeal membrane oxygenation machine in 2023 was USD 557.1 million. The industry is anticipated to exhibit a Y-o-Y growth of 4.6% in 2024.
An ECMO machine is one form of life support, temporarily replacing the function of the lungs and/or heart in supporting patients with severe respiratory and/or cardiac failure. It involves an outside circuit in which blood is pumped out to a membrane oxygenator outside the body; this removes carbon dioxide from the blood and adds oxygen before reinfusing the blood back to the patient.
ECMO machines can be employed in nearly every setting where medical devices are used, ranging from intensive care units to operating rooms and emergency medical services. They are generally encouraged as a bridge-to-recovery or transplantation modality or even as a means of supporting an individual during critical procedures.
Global Extracorporeal Membrane Oxygenation Machine Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 557.1 million |
| Estimated Size, 2024 | USD 582.2 million |
| Projected Size, 2034 | USD 904.1 million |
| Value-based CAGR (2024 to 2034) | 4.5% |
Improvements in ECMO technology are among the major drivers of the ECMO machine market. Improvements in design, material, and functionality enhance the efficiency, safety, and ease of use of ECMO machines, thereby spreading their adoption. More compact and portable machines have increased their use to emergency medical services and, thereby, remote areas.
Moreover, the employment of advanced sensor and monitoring systems permits real-time measurements and monitoring of patient parameters. This enables early detection of possible complications and hence improves patient safety.
Such advancements in technology provide more confidence to healthcare professionals in using ECMO machines, which further increases the utilization of these machines in various clinical settings. Consequently, more patients are getting saved with this technology, therefore driving the growth in the ECMO machine market.
The market for ECMO is growing with increasing applications and adaptations in pediatric and neonatal care settings. Respiratory as well as cardiac failure is found to be a common cause of death in pediatric and neonatal patients; life support therapy using ECMO is increasingly provided to such patients to treat such congenital defects.
The technology involved in ECMO has improved considerably with time as ECMO now can be adapted according to the peculiar needs of pediatric and neonatal patients. These advancements in technology have contributed to lower mortality. This has increased the adoption of such machines in neonatology.
The table below compares the compound annual growth rate (CAGR) for the global extracorporeal membrane oxygenation machine market from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 5.5%, followed by a slightly lower growth rate of 4.9% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 5.5% (2023 to 2033) |
| H2 | 4.9% (2023 to 2033) |
| H1 | 4.5% (2024 to 2034) |
| H2 | 4.2% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 4.5% in the first half and remain relatively moderate at 4.2% in the second half. In the first half (H1) the market witnessed a decrease of 100 BPS while in the second half (H2), the market witnessed a decrease of 70 BPS.
Increasing Prevalence of Cardiac and Respiratory Conditions Driving the Market Growth
This rising incidence of cardiopulmonary disorders presents a major concern and, therefore, drives the need for advanced medical support such as ECMO machines. Cardiopulmonary disorders can be summed up as conditions that relate to or affect the heart and lungs-for instance, syndrome and cardiogenic shock Treatment.
In acute respiratory distress syndrome (ARDS), the small air sacs in the lungs get filled with fluid, which makes the passage of oxygen into the blood difficult. It can further progress to critical breathing problems where external support is needed to aid breathing. Cardiogenic shock is another critical condition where the heart suddenly fails to pump adequate blood to fulfill the needs of the body, thus causing organ failure if not managed quickly.
As the number of such patients increases, the demand for ECMO machines becomes even bigger. ECMO machines replace the jobs of the heart and lungs, allowing these organs to rest and recover. This technology has become integral in the intensive care unit for the treatment of patients non-responsive to other treatments. The burgeoning incidence of cardiopulmonary disorders is a prime driver for the ECMO machine industry.
Development of Portable and User-Friendly ECMO Devices creates future growth opportunity
Technological advances are revolutionizing the practice of critical care. Although lifesaving, conventional ECMO machines remain very cumbersome, and complex, and demand high specialization from a medical team to operate them.
This makes their use very difficult in large, well-prepared hospitals and results in significant complications in the implementation of ECMO support on an emergency basis or in locations with poorly developed medical infrastructure.
With these barriers, there have been efforts to develop more user-friendly and portable ECMO units. Such newer models are assumed to embody basic dimensions that are both smaller and lighter yet carry the necessary high-level functions to support severely ill patients with acute heart and lung failure.
Portable ECMO machines can be used more flexibly in several settings: patient transport, smaller hospitals, and potentially outpatient. This portability is key to making ECMO therapy more readily available, even in emergency settings when each passing moment is of vital importance.
The ease of use would enable a wider array of professionals to operate the machines with minimal specialized training. Finally, with such a surge in the availability in general of ECMO devices, patient outcomes and the more widespread acceptance of ECMO technology can be assured.
Growing Focus on Minimally Invasive ECMO Procedures
The trend toward less invasive ECMO procedures is increasing in popularity because these procedures provide patients with a much safer and more accessible treatment procedure. In such a manner, minimally invasive ECMO procedures help diminish those risks by the minimal extent of surgical invasion and application of more advanced techniques.
It technically renders a less traumatic procedure for the patient, renders shorter recovery times, and lowers the risk of complications. In such a way, a larger patient population can safely benefit from ECMO procedures. This tendency is also aimed at the wider availability of ECMO. As procedural complexities and risks are reduced, more hospitals can carry out the treatment.
This allows more access to life-saving treatment for many people, regardless of their place of residence. With the trend of healthcare providers and patients preferring less invasive options, the market for the ECMO machine is increasingly becoming sensitive to this preference by fostering innovation in and widening the adoption of cutting-edge, minimally invasive techniques in critical care.
Technological developments can hence be foreseen to lead to an extension of the role of minimally invasive ECMO as part of standard critical care.
High Cost of ECMO Machines and Procedures may restrain the Market Growth
In patients with heart or lung failure, extracorporeal membrane oxygenation is pivotal life support. That therein lies the rub-that the hundreds of thousands that ECMO machines often cost-may just well be considered one lone, major obstacle to using these wonderful machines.
This is due to advanced technology and materials used for its manufacturing. Another factor that adds to their overall cost is maintenance and operation costs related to these machines. ECMO procedures require special teams of health personnel, including surgeons, nurses, and percussionists-all adding to the overall cost of treatment.
Moreover, this price does not apply to the machine itself. The period of stay in ICUs for the patient under ECMO treatment is quite long, which increases the cost of hospitalization. This becomes unaffordable to a large number of health providers, especially those coming from more deprived areas or coming from small hospitals.
This high-cost limits access to ECMO, mostly in developing countries, raising concerns about the affordability of this life-saving technology.
The global extracorporeal membrane oxygenation machine industry recorded a CAGR of 3.8% during the historical period between 2019 and 2023. The growth of extracorporeal membrane oxygenation machine industry was positive as it reached a value of USD 904.1 million in 2034 from USD 582.2 million in 2024.
Historically, life-threatening cardiac and respiratory failures have been managed using ventilators and medications, with an extremely poor prognosis for the most severe cases. The modalities were often unable to provide adequate oxygenation, leading to extremely high mortality.
ECMO has revolutionized this approach. Unlike the traditional method, in ECMO oxygenation of the blood occurs outside the body, making it literally a lifeline for patients unresponsive to traditional treatments. In ECMO, heart and lungs are at rest, recovering and considerably improving the chances of survival in severe cases.
With the increasing incidences of critical cardiopulmonary diseases, such as acute respiratory distress syndrome, heart failure, etc. the demand for advanced life-support technologies is likely to grow. The increasing prevalence of such serious conditions, powered by factors like rapid aging and the long-lasting effects of COVID-19, is lending importance to ECMO machines in critical care.
Furthermore, due to technological advancement such as portable or user-friendly ECMO devices can further increase demand for such machines. The innovations are making ECMO more accessible, easier to use, and even easier for institutions that are further from the latest medical project technologies.
Furthermore, the growing awareness of the life-saving potential of ECMO and expanded use in the pediatric and neonatal segment is pushing up the market. The market has a boom with a continuous rise due to the inflow of investments in healthcare infrastructure and upgradation of technology with regard to ECMO.
Tier 1 companies are the industry leaders as they hold a substantial 46.6% market share worldwide. These companies have generated revenue over USD 100 million. These companies have large product portfolio and a high production capacity.
These industry leaders stand out for having a wide geographic reach, a strong customer base, and substantial experience in manufacturing. They offer a variety of product, and have a strong brand loyalty. Prominent companies within tier 1 include Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Getinge Group, and Terumo Cardiovascular Systems Corporation.
Mid-size businesses with annual revenue between USD 50 and USD 100 million and which are capturing a market share of 27.7% in global market, and that are based in particular areas and have a significant impact on the local market are considered Tier 2 companies.
These companies have regional presence and in-depth industry expertise. These companies invests in newer technology and follows good manufacturing practices (GMP). These companies also collaborate with bigger companies so as to get competitive edge. Prominent companies in tier 2 include Microport, Origin Biomedical, and Nipro Corporation,
Tier 3 companies, although, smaller but are essential for the market. They have limited reach and mostly operate in few countries. They have lesser revenue as compared with tier 1 and tier 2 companies. The companies such as Livanova plc, Euro sets S.R.L., Cytosorbents Corporation, Abiomed and other falls under this category. They specialize in specific products and cater to niche markets, adding diversity to the industry.
The section below covers the industry analysis for the extracorporeal membrane oxygenation machine market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 81.6% through 2034. In Asia Pacific, China is projected to witness a CAGR of 4.5% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 1.4% |
| Germany | 1.4% |
| France | 2.3% |
| UK | 1.6% |
| China | 4.5% |
| India | 5.1% |
| South Korea | 3.5% |
Germany’s extracorporeal membrane oxygenation machine market is expected to exhibit a CAGR of 1.4% between 2024 and 2034. The Germany holds highest market share in European market.
The German government is making huge investments in the healthcare infrastructure, realizing new and better technology could bring about favorable patient outcomes. Part of these efforts is seen in the improvement of the critical care facilities, where part of includes putting up ECMO machines in hospitals.
The country's health policies encourage the use of frontier technologies and have even set subsidies to improve their ICU facilities. These subsidies also intend to be used for the readiness of the health workforce to ensure the efficient handling of complicated ECMO machines.
Notably, during the COVID-19 pandemic, the government of Germany gave fully fledged financial subsidies to scale ECMO capacity for the increase in critically ill respiratory cases. These steps not only support the application of ECMO machines but also spur innovation in the field and position Germany as a premier market for ECMO technology throughout Europe.
The USA market is anticipated to grow at a CAGR of 1.4% throughout the forecast period.
One major driving force behind the ECMO market in the USA is the increased rate of cardiopulmonary disorders. ARDS, COPD, and heart failure are some life-threatening conditions gaining popularity due to an aging population, increased prevalence of obesity, and lifestyle-induced diseases. Moreover, the after-effects of COVID-19 have further enhanced the prevalence of serious respiratory and cardiac disorders in USA
As these disorders grow, so does the need for advanced life-support systems like ECMO machines, which the patient requires to get crucial assistance in cases where other traditional treatments are insufficient. The USA healthcare system is, therefore, creating a surge in demand for ECMO technology in intensive care units, mainly among patients with severe cardiopulmonary failure.
This increasing demand strengthens the market growth as hospitals seek to invest in ECMO machines to enhance overall critical care competencies and improve patient outcomes.
China is expected to hold a dominating position in the East Asia market of extracorporeal membrane oxygenation machines and is anticipated to grow at a CAGR of 4.5% throughout the forecast period.
The growing adoption of ECMO in pediatric and neonatal care is one of the key drivers for the industry in China. With the country’s developing healthcare sector, more attention is paid to bettering the clinical outcomes of infants and children with life-critical cardiorespiratory diseases.
For conditions such as congenital heart defects, respiratory distress syndrome, and other serious infections in newborns; ECMO provides a lifesaving resource when conventional therapies fail.
China has been investing in specialized pediatric and neonatal intensive care units within major hospitals, and ECMO machines are finding a place as key devices. Therefore, demand in China is being fueled by the Chinese government's commitment to improving health services for children as well as by the increasing level of knowledge among healthcare professionals of ECMO's efficacy in pediatric care.
The section contains information about the leading segments in the industry. Based on product, the ECMO machines segment is expected to account for 78.5% of the global market share in 2024.
| Product | ECMO Machines |
|---|---|
| Value Share (2024) | 78.5% |
The ECMO machines segment is expected to dominate the market in terms of revenue, accounting for almost 78.5% of the market share in 2024.
The segment of ECMO machines is poised to dominate the extracorporeal membrane oxygenation market owing to its vital role in handling severe cardiac and respiratory failure. This machine gives critical life support through the oxygenation of blood outside the body, and allows both the heart and lungs of the patients to rest and recover.
Advanced capabilities are increasingly preferred in critical care due to superior support and improved survival rates. Other advancements in ECMO technologies include compact models with expanded efficiency, allowing these machines to be more appropriate and common.
Also, the rise in chronic diseases and the complexity of the needs of patients in general drive the demand for ECMO machines. Expensive as it is, the advantage this life-support machine has in sustaining patients' lives and improving recovery outcomes places it at the leading edge of market attention and underlines leadership in its segment.
| Service Type | Infrastructure |
|---|---|
| Value Share (2024) | 45.7% |
By service type, the infrastructure segment is projected to hold a major market share of 45.7% in 2024.
The infrastructure segment is anticipated to dominate due to its supporting role in installation, maintenance, and operational efficiency. This infrastructure segment includes all essential components necessary for establishing and maintaining ECMO equipment, comprising specialized facilities, technical support, and training for health professionals.
The technology behind ECMO is developing and getting more common. With increasing demand, the infrastructure of having ECMO on board-both physical and technical-is fast growing in hospitals and medical centers for proper functioning and integration.
It is assumed that, with the growing concern for advanced care and an expansion in the utilization of ECMO across different healthcare settings, the demand and importance of this segment would increase, thus leading this infrastructure segment to the front position of market forces.
The extracorporeal membrane oxygenation machine market is slightly concentrated. There are large number ECMO manufacturer in the global market involved in developing novel products so that they can meet their customer’s needs. However, the market is dominated by few top players such as Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Getinge Group, and Terumo Cardiovascular Systems Corporation.
Prominent producers of extracorporeal membrane oxygenation machine products are concentrating on growing internationally in order to increase their revenue and increase the size of their sales footprint. These companies often collaborated with other research institutes to develop more advanced devices.
Manufacturers utilize various key strategies such as agreements, product launches, research sponsorship, and strategic collaborations to boost product sales and establish their market presence.
Recent Industry Developments in Extracorporeal Membrane Oxygenation Machine Market
In terms of product, the industry is divided into ECMO machines (portable devices and static devices) and software
In terms of service type, the industry is segregated into application, middleware, and infrastructure
In terms of component, the industry is divided into pumps, oxygenators, controllers, cannula, and accessories.
In terms of modality, the industry is segregated into veno-venous, veno-arterials, and arterio-venous
In terms of end user, the industry is segregated into neonates, pediatrics, and adults
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global extracorporeal membrane oxygenation machine industry is projected to witness CAGR of 4.5% between 2024 and 2034.
The global extracorporeal membrane oxygenation machine industry stood at USD 557.1 million in 2023.
The global extracorporeal membrane oxygenation machine industry is anticipated to reach USD 904.1 million by 2034 end.
China is expected to show a CAGR of 4.5% in the assessment period.
The key players operating in the global extracorporeal membrane oxygenation machine industry include Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, and Abiomed.
Explore Similar Insights
Extracorporeal Membrane Oxygenation Machine Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
